Sorrento Therapeutics Inc (NASDAQ:SRNE) shares were moving to the downside Monday.
What Happened: The FDA announced Saturday that it has issued emergency use authorization to Yale University's SalivaDirect COVID-19 diagnostic test, which uses a method to process saliva samples for diagnosing COVID-19 infection.
Sorrento shares found strong upward momentum in late July and in early August after the company said it has entered into an agreement with Columbia University to license a rapid saliva test for SARS-CoV-2.
The shares gave back some of the gains after short seller Hindenburg called the announcement a stock-pumping initiative last week.
Why It's Important: With much of the market value added to Sorrento's stock coming on the back of announcements regarding COVID-19 antibody treatment, vaccine and diagnostic test sin development, Yale University's breakthrough is likely to be a setback for the stock.
The stock could test the levels it traded at ahead of the announcement of the licensing deal with Columbia University.
SRNE Price Action: Sorrento shares were down 5.63% at $11.74 at last check Monday.
Related Links:
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The Week Ahead In Biotech: Spotlight On Gilead, BioMarin FDA Decisions, IPOs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
